Core Points - The company announced an adjustment in the total cash dividend amount for the first half of 2025, maintaining a cash dividend of 0.80 yuan per 10 shares (including tax) [2] - The total cash dividend amount was adjusted from 16,967,901.20 yuan (including tax) to 16,967,993.52 yuan (including tax) [2] - The adjustment is due to the increase in the number of shares participating in profit distribution as a result of the company's publicly issued "Haoyuan Convertible Bonds" being in the conversion period [2]

Market Overview - The medical services sector experienced a decline of 2.91% on October 13, with Haoyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the medical services sector included: - Meinian Health: closed at 5.29, up 3.52% with a trading volume of 2.2848 million shares [1] - ST Biological: closed at 9.15, up 2.69% with a trading volume of 23,400 shares [1] - International Medical: closed at 4.98, up 2.26% with a trading volume of 356,400 shares [1] - Major decliners included: - Haoyuan Pharmaceutical: closed at 75.50, down 6.79% with a trading volume of 75,700 shares [2] - Boteng Co.: closed at 23.34, down 6.27% with a trading volume of 224,900 shares [2] - Kailaiying: closed at 105.42, down 5.04% with a trading volume of 57,800 shares [2] Capital Flow - The medical services sector saw a net outflow of 870 million yuan from institutional investors, while retail investors contributed a net inflow of 601 million yuan [2][3] - Key stocks with significant capital flow included: - Sanbo Brain Science: net inflow of 21.51 million yuan from institutional investors [3] - International Medical: net inflow of 20.51 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical: net inflow of 10.59 million yuan from institutional investors [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-117 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于实施 2025 年半年度权益分派调整可转债 转股价格暨转股复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2025 年半年度权益分派，上海皓元医药股份有限公司（以下简称"公 司"）的相关证券停复牌情况如下：权益分派实施公告披露日前一交易日（2025 年 10 月 13 日）至权益分派股权登记日（2025 年 10 月 21 日）期间，本公司可转 债将停止转股，2025 年 10 月 22 日起恢复转股。 | 证券代码 | 证券简称 | 停复牌类 | 停牌起 | 停牌期 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | 型 | 始日 | 间 | | | | 118051 | 皓 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-115 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2025 年半年度利润分配现金分红 总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 现金分红总额调整情况：上海皓元医药股份有限公司（以下简称"公 司"）2025 年半年度拟向全体股东每 10 股派发现金红利 0.80 元（含税）维持不 变，派发现金红利总额由 16,967,901.20 元（含税）调整为 16,967,993.52 元（含 税）。 本次调整原因：因公司公开发行的"皓元转债"目前处于转股期内，导 致公司实际参与利润分配的股份数量增加，公司拟维持每股分配金额不变，相 应调整 2025 年半年度现金分配总额。 一、调整前利润分配方案 根据公司 2024 年年度股东大会的授权，公司分别于 2025 年 8 月 26 日召开 第四届董事会审计委员会第五次会议、2025 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-116 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/21 | 2025/10/22 | 2025/10/22 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 4 月 18 日的2024年年度股东大会授权公司董 事会制定，并经公司 2025 年 8 月 27 日召开的第四届董事会第十一次会议审议通 过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1 是 ...

10月13日，皓元医药跌5.05%，截至发稿，报76.91元/股，成交1.78亿元，换手率1.07%，总市值163.13 亿元。 资料显示，上海皓元医药股份有限公司位于上海市浦东新区张衡路1999弄3号楼，成立日期2006年9月30 日，上市日期2021年6月8日，公司主营业务涉及小分子药物发现领域的分子砌块和工具化合物的研发, 以及小分子药物原料药、中间体的工艺开发和生产技术改进,为全球医药企业和科研机构提供从药物发 现到原料药和医药中间体的规模化生产的相关产品和技术服务。主营业务收入构成为：分子砌块、工具 化合物和生化试剂68.97%，其中:产品销售63.42%，原料药和中间体、制剂30.46%，其中:技术服务 5.55%，其他(补充)0.57%。 从基金十大重仓股角度 数据显示，红塔红土基金旗下1只基金重仓皓元医药。红塔红土医药精选股票发起式A（020331）二季 度持有股数1.3万股，占基金净值比例为4.93%，位居第四大重仓股。根据测算，今日浮亏损失约5.32万 元。 红塔红土医药精选股票发起式A（020331）基金经理为曹阳。 截至发稿，曹阳累计任职时间2年32天，现任基金资产总规模1275.43 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-114 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 具体变动情况如下： 1 上海皓元医药股份有限公司 关于控股股东可转债持有比例变动达到 10%的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债配售情况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元，期限 6 年。 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 公司 ...

Group 1 - The core point of the news is that Haoyuan Pharmaceutical's stock price dropped by 5.24% to 81.00 CNY per share, with a trading volume of 237 million CNY and a turnover rate of 1.35%, resulting in a total market capitalization of 17.18 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the research and development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value, with an estimated floating loss of approximately 110,200 CNY [2] - The Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) was established on April 1, 2017, with a latest scale of 56.68 million CNY, achieving a year-to-date return of 43.74% and a one-year return of 40.63% [2] - The fund manager, Xing Cheng, has been in position for 3 years and 203 days, with the fund's total asset size at 252 million CNY, achieving the best return of 87.69% and the worst return of -29.15% during his tenure [3]

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) has shown a slight decline at the opening, with a reported drop of 0.33% to 1.517 yuan, indicating market volatility and investor sentiment towards the fund's holdings [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) has a performance benchmark based on the Zhongzheng 1000 Index return [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 52.12% [1] - Over the past month, the fund has recorded a return of 5.46% [1] Group 2: Major Holdings - Key stocks in the fund include Xiangdian Co., which opened down 0.55%, and Haoyuan Pharmaceutical, which fell by 1.15% [1] - Other notable stocks include Xinqianglian, which rose by 0.43%, and Chujian New Materials, which increased by 0.40% [1] - The fund also holds shares in Nanwei Software, Zhenlei Technology, and Hongsoft Technology, with varying performance [1]

Core Insights - On October 9, Haoyuan Pharmaceutical's stock rose by 3.49%, with a trading volume of 508 million yuan [1] - The company reported a financing buy-in of 70.22 million yuan and a net financing buy-in of 3.93 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Haoyuan Pharmaceutical was 416 million yuan, indicating a high level of trading activity [1] Financing Summary - On October 9, Haoyuan Pharmaceutical had a financing buy-in of 70.22 million yuan, with a current financing balance of 414 million yuan, representing 2.29% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Short Selling Summary - On October 9, Haoyuan Pharmaceutical repaid 4,660 shares in short selling and sold 3,000 shares, amounting to 256,400 yuan at the closing price [1] - The remaining short selling volume was 15,000 shares, with a short selling balance of 1.28 million yuan, which is above the 70th percentile of the past year [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42% [2] - As of September 19, the number of shareholders increased by 17.93% to 12,800, with an average of 16,527 circulating shares per person, a decrease of 12.82% [2] Financial Performance - For the first half of 2025, Haoyuan Pharmaceutical achieved a revenue of 1.311 billion yuan, representing a year-on-year growth of 24.20% [2] - The net profit attributable to shareholders was 152 million yuan, showing a significant year-on-year increase of 115.55% [2] Dividend Information - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 143 million yuan in dividends, with 103 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 6.2611 million shares, an increase of 329,200 shares from the previous period [3] - The fund "China Europe Medical Health Mixed A" ranked fifth among circulating shareholders, holding 6.1185 million shares, a decrease of 2.7776 million shares from the previous period [3]